Treatment with F-15,063 resulted in induction of c-fos and fosB mRNA expression in the prefrontal cortex.

In the striatum, F-15,063 treatment resulted in induction of all IEGs studied (c-fos, fosB, zif268, c-jun, junB, nor1, nur77, arc).

[2] F-15,063 was tested in several animal models that predict antipsychotic activity to help determine the behavioral profile.

Administration of F-15,063 blocked amphetamine and ketamine induced hyperlocomotion, but did not affect baseline, spontaneous locomotor activity.

Despite this, there was still a high (65%) level of central D2 occupancy at 4 hours, and it retained its full antipsychotic potential at this time point.